May & Baker Nigeria Plc, Nigeria’s leading pharmaceutical manufacturer, has in October this year announced that Daisy Danjuma will succeed Theophilus Danjuma as Director and Chairman of the Board of Directors of the company.
This comes after the immediate former chairman Mr. Theophilus Danjuma chose to retire from his Director and Chair of the company’s board in September 2019
A disclosure notice sent to the Nigerian Stock Exchange confirmed that Daisy Danjuma, wife of the businessman, has been appointed as the new Chairman of the Board with immediate effect.
Mrs Danjuma was first appointed to the Board of Directors of the company on 30th July,1999 where she served until October 2003.
She is a law graduate of the Ahmadu Bello University, Zaria with over four decades post-call experience having been called to the Nigerian bar in 1977.
The statement said that she worked as a State Counsel in Lagos State Ministry of Justice (DPP), a pioneer legal counsel to the Legal Aid Council and was Company Secretary/Legal Adviser to the Nigerian Television Authority (NTA) until 1992.
She served as the chairperson of South Atlantic Petroleum Limited from 1999 up to 2003 when she was elected Senator of the Federal Republic of Nigeria in 2003.
She is a member of the International Bar Association (IBA), the Nigerian Bar Association (NBA) and the International Federation of Female Lawyers (FIDA).
Mrs Danjuma is a Trustee of the Obafemi Awolowo Foundation and H I D Awolowo Foundation also the Chair, Board of Trustees of Lagos Public Interest Law Partnership and currently the Executive Vice Chairman of South Atlantic Petroleum Limited.
May & Baker, Nigeria Plc was founded on September 4, 1944 as Nigeria’s first pharmaceutical company.
In 1979, following the indigenisation decree which required that foreign interests in companies operating in Nigeria be of a minority nature, May & Baker, United Kingdom relinquished 60 per cent of its equity holding in May & Baker Nigeria to Nigerians while retaining 40 per cent.
The company thereby began an aggressive expansion and diversification programme since 2005 which has culminated in the creation of new businesses and subsidiaries.
In 2006, the company constructed a multi-billion-naira food processing factory, constructed a local plant to produce anti-retroviral drugs in Nigeria.
The company also in 2011 commissioned its World Health Organization Standard Pharmaceutical production facility to produce a wide range of products for the Nigerian and West African market.
Mrs Danjuma’s appointment is expected to help the company to move towards achieving its vision of becoming a leading Health Care Brand in Sub-Saharan Africa.
